Addex Therapeutics Ltd. (ADXN) Equity Ratio (2022 - 2024)

Addex Therapeutics' Equity Ratio history spans 3 years, with the latest figure at 0.91 for Q4 2024.

  • For Q4 2024, Equity Ratio rose 267.25% year-over-year to 0.91; the TTM value through Dec 2024 reached 0.91, up 267.25%, while the annual FY2024 figure was 0.91, 267.25% up from the prior year.
  • Equity Ratio for Q4 2024 was 0.91 at Addex Therapeutics, up from 0.25 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.91 in Q4 2024 and bottomed at 0.25 in Q4 2023.
  • The 3-year median for Equity Ratio is 0.59 (2022), against an average of 0.58.
  • The largest annual shift saw Equity Ratio tumbled 58.4% in 2023 before it soared 267.25% in 2024.
  • A 3-year view of Equity Ratio shows it stood at 0.59 in 2022, then crashed by 58.4% to 0.25 in 2023, then skyrocketed by 267.25% to 0.91 in 2024.
  • Per Business Quant, the three most recent readings for ADXN's Equity Ratio are 0.91 (Q4 2024), 0.25 (Q4 2023), and 0.59 (Q4 2022).